Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial - Agarwal, Neeraj; Azad, Arun A; Carles, Joan; Fay, Andre P; Matsubara, Nobuaki; Heinrich, Daniel; Szczylik, Cezary; De Giorgi, Ugo; Young Joung, Jae; Fong, Peter C C; Voog, Eric; Jones, Robert J; et al. (The lancet, 2023)
Online verfügbar: 4. Juni 2023, Artikelversion: 20. Juli 2023